Skip to main content
Log in

Radiation therapy approaches to the treatment of high-risk prostate cancer

  • Published:
Current Prostate Reports

Abstract

Radiation therapy modalities have been shown to offer patients a nonoperative option for definitive treatment of localized prostate cancer as well as options for adjuvant or salvage therapy in high-risk prostate cancer patients. In patients with high-risk, localized disease, radiation therapy with or without adjuvant hormonal therapy is considered an excellent treatment option because of its efficacy within the prostate and among local periprostatic structures, addressing micrometastatic disease. Following radical prostatectomy in patients with high-risk or recurrent disease, radiotherapy can increase oncologic efficacy in both the adjuvant and salvage setting. Continued studies are underway to address ongoing concerns of sparing surrounding tissues unnecessary radiation while administering high-dose radiation to the prostate and targeted periprostatic structures. Newer technologies are using real-time imaging and computer-simulated motion calculation to adjust for physiological organ motion with respect to bony landmarks classically used to map areas of radiation administration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Scher HI, Leidel SA, Fuks Z, et al.: Cancer of the prostate. In Cancer: Principles and Practice of Oncology edn 7. Edited by Devita VT Jr, Hellman S, Rosenberg SA. Philadelphia: Lippincott Williams & Wilkins; 2005:1192–1295.

    Google Scholar 

  2. D’Amico AV, Whittington R, Malkowicz SB, et al.: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969–974.

    Article  PubMed  Google Scholar 

  3. Zelefsky MJ, Chan H, Hunt M, et al.: Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006, 176:1415–1419.

    Article  PubMed  Google Scholar 

  4. D’Amico AV, Moul JW, Carroll PR, et al.: Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003, 95:1376–1383.

    Article  PubMed  Google Scholar 

  5. Stephenson AJ, Scardino PT, Eastham JA, et al.: Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 2006, 98:715–717.

    Article  PubMed  Google Scholar 

  6. Mitchell RE, Chang SS: Current controversies in the treatment of high-risk prostate cancer. Curr Opin Urol 2008, 18:263–268.

    Article  PubMed  Google Scholar 

  7. Loeb S, Kettermann A, Ferrucci L, et al.: PSA doubling time and PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. Eur Urol 2008, 54:1073–1080.

    Article  PubMed  Google Scholar 

  8. Pasteau O: Traitment du cancer de la prostate par le Radium. Rev Mal Nutr 1911, 363–367.

  9. Young HH: Technique of radium treatment of cancer of the prostate in seminal vesicles. Surg Gynecol Obstet 1922, 34:93–98.

    Google Scholar 

  10. Denning CL: Carcinoma of the prostate seminal vesicles treated with radium. Surg Gynecol Obstet 1922, 34:99–118.

    Google Scholar 

  11. Whitmore WF Jr, Hilaris B, Grabstald H: Retropubic implantation of iodine 125 in the treatment of prostatic cancer. J Urol 1972, 108:918–920.

    PubMed  Google Scholar 

  12. Holm HH, Juul N, Pedersen JF, et al.: Transperineal I-125 seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 1983, 130:283–286.

    PubMed  CAS  Google Scholar 

  13. Bagshaw MA, Kaplan HS, Sageiman RH: Linear accelerator supervoltage radiotherapy: carcinoma of the prostate. Radiology 1965, 85:121–129.

    PubMed  CAS  Google Scholar 

  14. Bagshaw MA, Ray RR, Pistenma DA, et al.: External beam radiation therapy: primary carcinoma of the prostate. Cancer 1975, 36:723–728.

    Article  PubMed  CAS  Google Scholar 

  15. Roehl KA, Han M, Ramos CG, et al.: Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004, 172:910–914.

    Article  PubMed  Google Scholar 

  16. Han M, Partin AW, Zahurak M, et al.: Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003, 169:517–523.

    Article  PubMed  Google Scholar 

  17. Sylvester JE, Grimm PD, Blasko JC, et al.: 15-year biochemical relapse free survival in clinical stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol Phys 2007, 67:57–64.

    Article  PubMed  Google Scholar 

  18. Galalae RM, Martinez A, Mate T, et al.: Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004, 58:1048–1055.

    Article  PubMed  Google Scholar 

  19. Nieder AM, Porter MP, Soloway MS: Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J Urol 2008, 180:2005–2009.

    Article  PubMed  Google Scholar 

  20. Potters L, Morgenstern C, Calugaru E, et al.: 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2005, 173:1562–1566.

    Article  PubMed  Google Scholar 

  21. Roach M 3rd, Hanks G, Thames HJ, et al.: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65:965–974.

    Article  PubMed  Google Scholar 

  22. Pollack A, Zagars GK, Smith LG, et al.: Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 2000, 18:3904–3911.

    PubMed  CAS  Google Scholar 

  23. Zietman AL, DeSilvio ML, Slater JD, et al.: Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005, 294:1233–1239.

    Article  PubMed  CAS  Google Scholar 

  24. Boehmer D, Maingon P, Poortmans P, et al.: Guidelines for primary radiotherapy of patients with prostate cancer. Radiother Oncol 2006, 79:259–269.

    Article  PubMed  Google Scholar 

  25. Chao KK, Goldstein NS, Yan D, et al.: Clinicopathologic analysis of extracapsular extension in prostate cancer: should the clinical target volume be expanded posterolaterally to account for microscopic extension? Int J Radiat Oncol Biol Phys 2006, 65:999–1007.

    Article  PubMed  Google Scholar 

  26. Kestin L, Goldstein N, Vicini F, et al.: Treatment of prostate cancer with radiotherapy: should the entire seminal vesicles be included in the clinical target volume? Int J Radiat Oncol Biol Phys 2002, 54:686–697.

    Article  PubMed  Google Scholar 

  27. Ling CC: Permanent implants using Au-198, Pd-103 and I-125: radiobiological considerations based on the linear quadratic model. Int J Radiat Oncol Biol Phys 1992, 23:81–87.

    Article  PubMed  CAS  Google Scholar 

  28. Cha CM, Potters L, Ashley R, et al.: Isotope selection for patients undergoing prostate brachytherapy. Int J Radiat Oncol Biol Phys 1999, 45:391–395.

    Article  PubMed  CAS  Google Scholar 

  29. Kupelian PA, Willoughby TR, Reddy CA, et al.: Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007, 68:1424–1430.

    Article  PubMed  Google Scholar 

  30. Merrick GS, Butler WM, Wallner KE, et al.: Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005, 61:32–43.

    Article  PubMed  CAS  Google Scholar 

  31. Blasko JC, Grimm PD, Sylvester JE, et al.: Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000, 46:839–850.

    Article  PubMed  CAS  Google Scholar 

  32. Bolla M, Collette L, Blank L, et al.: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002, 360:103–106.

    Article  PubMed  CAS  Google Scholar 

  33. Pilepich MV, Winter K, Lawton CA, et al.: Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005, 61:1285–1290.

    Article  PubMed  CAS  Google Scholar 

  34. Granfors T, Modig H, Damber JE, et al.: Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone. J Urol 2006, 176:544–547.

    Article  PubMed  Google Scholar 

  35. Lawton CA, Bae K, Pilepich M, et al.: Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02. Int J Radiat Oncol Biol Phys 2008, 70:437–441.

    Article  PubMed  CAS  Google Scholar 

  36. Shapiro EY, Rais-Bahrami S, Morgenstern C, et al.: Long-term outcomes in younger men following permanent prostate brachytherapy. J Urol 2009 (in press).

  37. Magheli A, Rais-Bahrami S, Humphreys EB, et al.: Impact of patient age on biochemical recurrence rates following radical prostatectomy. J Urol 2007, 178:1933–1937.

    Article  PubMed  Google Scholar 

  38. Haese A, Epstein JI, Huland H, et al.: Validation of a biopsy-based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostate carcinoma. Cancer 2002, 95:1016–1021.

    Article  PubMed  Google Scholar 

  39. Allaf ME, Palapattu GS, Trock BJ, et al.: Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 2004, 172:1840–1844.

    Article  PubMed  Google Scholar 

  40. Lawton CA, DeSilvio M, Roach M 3rd, et al.: An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 2007, 69:646–655.

    Article  PubMed  Google Scholar 

  41. Stone NN, Potters L, Davis BJ, et al.: Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7–10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys (in press).

  42. Thompson IM Jr, Tangen CM, Paradelo J, et al.: Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006, 296:2329–2335.

    Article  PubMed  CAS  Google Scholar 

  43. Bolla M, van Poppel H, Collette L, et al.: Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005, 366:572–578.

    Article  PubMed  Google Scholar 

  44. Trabulsi EJ, Valicenti RK, Hanlon AL, et al.: A multiinstitutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology 2009 (in press).

  45. Trock BJ, Han M, Freedland SJ, et al.: Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008, 299:2760–2769.

    Article  PubMed  CAS  Google Scholar 

  46. Litwin MS, Gore JL, Kwan L, et al.: Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer 2007, 109:2239–2247.

    Article  PubMed  Google Scholar 

  47. Namiki S, Satoh T, Baba S, et al.: Quality of life after brachytherapy or radical prostatectomy for localized prostate cancer: a prospective longitudinal study. Urology 2006, 68:1230–1236.

    Article  PubMed  Google Scholar 

  48. Sanda MG, Dunn RL, Michalski J, et al.: Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008, 358:1250–1261.

    Article  PubMed  CAS  Google Scholar 

  49. Moinpour CM, Hayden KA, Unger JM, et al.: Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group Trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Onc 2008, 26:112–120.

    Article  Google Scholar 

  50. Abdel-Wahab M, Reis IM, Hamilton K: Second primary cancer after radiotherapy for prostate cancer: a seer analysis of brachytherapy versus external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008, 72:58–68.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Louis Potters.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rais-Bahrami, S., Vira, M.A. & Potters, L. Radiation therapy approaches to the treatment of high-risk prostate cancer. Curr prostate rep 7, 95–101 (2009). https://doi.org/10.1007/s11918-009-0014-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11918-009-0014-x

Keywords

Navigation